Nts are nonetheless an important step to additional confirm the prognostic worth of this gene signature. Furthermore, this is a retrospective study, so it is important to confirm the robustness of this five-gene signature inside a potential study in the future.CONCLUSIONIn summary, the study identified a brand new prognostic gene signature based on proliferation-related genes (FARSB, NOP58, CCT4, DHX37, and YARS). Besides, a nomogram according to the fivegene signature was constructed for clinical practice. The five-gene signature is often applied for survival prediction and danger stratification for HCC patients. Additionally, possible drugs targeting this gene signature deserve additional interest within the treatment of HCC.Information AVAILABILITY STATEMENTThe datasets presented within this study can be located in on the net repositories. The names of the repository/repositories and accession number(s) could be located in the article/ Supplementary Material.AUTHOR CONTRIBUTIONSYL developed the study and revised the manuscript. JuL collected and analyzed the information. JiL interpreted the information and drafted the manuscript. WL and WM revised the manuscript. All authors have study and approved the final manuscript. JuL and JiL contributed equally to this function and are co-first authors.SUPPLEMENTARY MATERIALThe Supplementary Material for this article might be identified on-line at: frontiersin.MES References org/articles/10.3389/fgene.2022.900380/ fullsupplementary-materialFrontiers in Genetics | frontiersin.orgJune 2022 | Volume 13 | ArticleLiu et al.Drugs Targeting a Gene Signature
pharmaceuticsArticleTailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Connected with Hypertension: A Preclinical StudyMahmoud M.Anti-Mouse CD28 Antibody Cancer A.PMID:28739548 Elsayed 1, , Moustafa O. Aboelez 2 , Mohamed S. Mohamed three , Reda A. Mahmoud 3 , Ahmed A. El-Shenawy three , Essam A. Mahmoud four , Ahmed A. Al-Karmalawy five , Eman Y. Santali six , Sameer Alshehri 7 , Mahmoud Elkot Mostafa Elsadek 8 , Mohamed A. El Hamd 9,10, and Abd El hakim Ramadan24Citation: Elsayed, M.M.A.; Aboelez, M.O.; Mohamed, M.S.; Mahmoud, R.A.; El-Shenawy, A.A.; Mahmoud, E.A.; Al-Karmalawy, A.A.; Santali, E.Y.; Alshehri, S.; Elsadek, M.E.M.; et al. Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study. Pharmaceutics 2022, 14, 1629. doi.org/10.3390/ pharmaceutics14081629 Academic Editor: Peter Timmins Received: 21 June 2022 Accepted: 28 July 2022 Published: 4 August 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.9Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al Azhar University, Assiut 71524, Egypt Division of Clinical Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt Division of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia Division of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia Division of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Merit University.
